Resolution Therapeutics Limited

Company description

Resolution Therapeutics develops specialised cell therapies aimed at treating inflammatory organ diseases.

Macropage cell therapy company

Resolution Therapeutics Ltd is based on a decade of research from the Forbes lab at the Centre for Regenerative Medicine and will be housed within the Centre building at Edinburgh BioQuarter. Cirrhosis is caused by long-term damage to the liver. More than 4,000 people a year in the UK die from cirrhosis with around 700 people needing a liver transplant. There are currently no therapies available and patients are at risk of progressing to decompensated cirrhosis, where the liver can no longer cope and the patient needs a transplant. Resolution Therapeutics Ltd is developing cell treatments to repair organ damage - including end-stage chronic liver disease. It has received funding of £26.6 million from Syncona Ltd, a specialist healthcare investment company. The investment is expected to enable Resolution to gain early clinical data for its first product. The new biopharmaceutical company is developing macrophage cell therapies. Macrophages are immune system cells involved in responses to injury, including the wound-healing process. Resolution is exploiting the ability of macrophages to stimulate organ repair following damage caused by disease. Resolution's first programme is an engineered macrophage to treat patients with compensated liver cirrhosis - where the liver is badly damaged but still functioning.

Project impact

Providing employment in Scotland.

Received £26m series 1 investment in late 2020 from VC therefore impacts will be reported in following years.